New Blood Filter Extends Pregnancies Threatened by Preeclampsia

Doctors have discovered a way to buy precious time for pregnancies threatened by one of the most dangerous complications in medicine.

Preeclampsia strikes up to 8% of pregnant people globally, causing dangerously high blood pressure, organ damage, and premature births. Until now, the only treatment was delivering the baby early, often before they were ready.

A new study published in Nature Medicine tested a different approach: filtering excess protein from the mother's blood. Researchers at Cedars-Sinai Health System in Los Angeles identified a culprit protein called soluble Flt-1, which the placenta makes naturally but can reach five times normal levels in preeclampsia patients.

Dr. Ravi Thadhani and his team created a filter with special antibodies that grab the excess protein as blood flows through. They tested it on 16 women with early preeclampsia who faced premature delivery.

The results were encouraging. Each treatment reduced the harmful protein by 17% and lowered blood pressure slightly. More importantly, it stabilized symptoms enough to delay delivery in most patients.

Pregnancies continued for a median of 10 extra days, with one woman gaining 19 additional days. Those extra days in the womb allowed babies to keep growing and getting stronger. The babies were still born preterm at a median of 31 weeks, but every day counts when it comes to avoiding complications from premature birth.

The Bright Side

This marks the first real innovation for preeclampsia treatment in decades. The condition hasn't spared any population and has long frustrated doctors who could only watch and wait before delivering early.

Dr. Thomas McElrath at Mass General Brigham called the safety results "encouraging." Researchers have worried for years that removing the protein might disrupt some protective balance in the body. Instead, both mothers and babies tolerated the treatment without major harm.

The study was small and didn't include a control group, so larger trials are needed to confirm how much time the treatment actually adds and whether it's truly safe. Some women experienced side effects like headaches and false labor, though doctors couldn't tell if the treatment or worsening preeclampsia caused them.

Still, for a condition that affects millions of pregnant people worldwide and has had no new treatments in generations, this represents genuine hope. The extra days could mean healthier babies and better outcomes for families facing one of pregnancy's scariest complications.